Lipocine (NASDAQ:LPCN) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN) in a research report report published on Thursday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Lipocine Price Performance

LPCN opened at $3.44 on Thursday. The business’s 50-day moving average is $4.11 and its two-hundred day moving average is $4.54. Lipocine has a 1 year low of $2.91 and a 1 year high of $11.79. The firm has a market capitalization of $18.40 million, a PE ratio of -4.53 and a beta of 1.42.

Hedge Funds Weigh In On Lipocine

An institutional investor recently raised its position in Lipocine stock. Geode Capital Management LLC grew its stake in shares of Lipocine Inc. (NASDAQ:LPCN) by 6.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 57,464 shares of the specialty pharmaceutical company’s stock after acquiring an additional 3,248 shares during the quarter. Geode Capital Management LLC owned about 1.07% of Lipocine worth $280,000 as of its most recent SEC filing. Institutional investors and hedge funds own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.